The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 10564 participants.
Also called NCT01975389
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 10,564 participants
- Sponsor
- Registry
-
NCT01975389 -
2013-002795-41
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT01975389. Randomized; quadruple masking; primary purpose prevention. Start 2013-10-29 (actual); primary completion 2017-04-03 (actual). Results posted on 2018-06-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
- Acronym
- SPIRE-2
- Condition
- Cardiovascular Disease
- Intervention (Drug)
- bococizumab (PF-04950615)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct01975389- Content hash
204312a1c914dc151196dec6ca7eef06133474596d7f13f461f31786c83e8cee